Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis
Objective: This study investigated the neuroprotective and neuromodulatory effects of dietary caffeic acid (CA) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian rat model Background: Parkinson’s disease (PD)…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Association Between Heterozygous Loss-of-Function Variants in the MCOLN1 Gene and α-Synucleinopathies
Objective: To evaluate the association between heterozygous loss-of-function variants in the MCOLN1 gene and α-synucleinopathies. Background: Lysosomes play a crucial role in cellular waste disposal,…A Case of Decreased Disability After Stroke: Lesional Modulation of Essential Tremor
Objective: We present a case of decreased disability following acute ischemic stroke and review lesional treatment of essential tremor. Background: Essential tremor is one of…Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication
Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Novel C-KIT/C-Abl Inhibitor BK40196 Alleviates Neurodegenerative Pathology And Improves Behavioral Performance In A53T Mice
Objective: Here we synthesized a novel c-KIT/c-Abl inhibitor BK40196 and investigated its effects on alpha-synuclein, neuro-inflammation , dopamine and behavior in A53T mice. Background: Inhibition…Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: A longitudinal study
Objective: To investigate whether chronic kidney disease (CKD) and proteinuria are associated with mortality rates in patients with Parkinson's disease (PD), using data from a large…The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model
Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
- « Previous Page
- 1
- …
- 334
- 335
- 336
- 337
- 338
- …
- 1942
- Next Page »